Related Experiment Video
Updated: May 31, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
Juliann Chmielecki1, Jasmine Foo, Geoffrey R Oxnard
1Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA.
Abstract:
Non-small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result of a secondary mutation within EGFR (T790M). Because both drugs were developed to target wild-type EGFR, we hypothesized that current dosing schedules were not optimized for mutant EGFR or to prevent resistance. To investigate this further, we developed isogenic TKI-sensitive and TKI-resistant pairs of cell lines that mimic the behavior of human tumors. We determined that the drug-sensitive and drug-resistant EGFR-mutant cells exhibited differential growth kinetics, with the drug-resistant cells showing slower growth. We incorporated these data into evolutionary mathematical cancer models with constraints derived from clinical data sets. This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance.
Insights
EGFR-mutant non-small cell lung cancer (NSCLC) patients develop resistance to TKIs like gefitinib. Mathematical modeling suggests new dosing strategies can delay resistance and prolong treatment benefits.
Area of Science:
- Oncology
- Pharmacology
- Mathematical Biology
Background:
- Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is treated with tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib.
- Acquired resistance to TKIs, often due to the EGFR T790M mutation, limits long-term patient benefit.
- Current TKIs target wild-type EGFR, suggesting suboptimal dosing for mutant EGFR and resistance prevention.
Purpose of the Study:
- To investigate optimized TKI dosing strategies for EGFR-mutant NSCLC.
- To explore methods for delaying the development of TKI resistance.
Main Methods:
- Development of isogenic TKI-sensitive and TKI-resistant cell line pairs modeling human tumors.
- Characterization of differential growth kinetics between sensitive and resistant EGFR-mutant cells.
- Application of evolutionary mathematical cancer models constrained by clinical data.
Main Results:
- Drug-resistant EGFR-mutant cells exhibited slower growth kinetics compared to sensitive cells.
- Mathematical modeling predicted alternative therapeutic strategies.
- These strategies showed potential for prolonging TKI clinical benefit.
Conclusions:
- Optimized TKI dosing schedules may overcome resistance mechanisms in EGFR-mutant NSCLC.
- Mathematical modeling is a valuable tool for predicting and optimizing cancer therapy.
- Further research into novel dosing strategies could improve outcomes for NSCLC patients.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...